賽諾醫療(688108.SH)半年度淨利預降360.02%
格隆匯7月20日丨賽諾醫療(688108.SH)披露半年度業績預虧公吿，經財務部門初步測算，公司預計2021年上半年度實現營業收入7,863.31萬元，與上年同期相比，減少9,781.29萬元，同比下降55.44%。
據悉，預計2021年半年度實現歸屬於上市公司股東的淨利潤為-8,154.22萬元，與上年同期相比，減少11,290.28萬元，同比下降360.02%。
另外，預計2021年半年度歸屬於上市公司股東的扣除非經常性損益後的淨利潤為-8,329.99萬元，與上年同期相比，減少11,149.42萬元，同比下降395.45%。
本期業績預虧的主要原因：
1、營業收入下降的主要原因
報吿期內，國家冠脈支架帶量集採政策於2021年1月1日起執行，醫院在手術過程中優先使用帶量集採中標產品，而公司在售第一代冠脈支架產品未被納入冠脈支架國家集採範圍之內，導致公司2021年上半年冠脈支架產品銷量較上年同期大幅下降85.61%，冠脈支架產品收入較上年同期減少12,378.23萬元，同比下降90.01%。與此同時，由於公司球囊產品(冠脈球囊和神經球囊)銷量繼續保持快速增長態勢，球囊產品銷量同比增長74.91%，球囊產品營業收入較去年同期增加2,618.64萬元，同比增長68.22%。
2、淨利潤下降的主要原因
報吿期內，由於(1)冠脈支架產品銷量大幅下降，公司生產產品的規模效應降低，產品生產成本未能與之同比例下降；(2)因拓展神經介入業務租賃廠房和團隊擴張，以及新產品取得註冊證後無形資產攤銷增加，致使本期管理費用較上年同期大幅增長；(3)公司保持冠脈業務銷售團隊的基本穩定並加大神經業務團隊的銷售人員引進力度，人工成本未減少，導致銷售費用並未與之同比例下降；(4)為夯實公司產品核心競爭力，不斷豐富公司各業務板塊產品線，公司持續保持較強的研發投入，預計2021年上半年研發支出(含資本化支出和費用化支出)佔營業收入比重為109.35%，較上年同期增加71.13個百分點，其中費用化研發支出預計較上年同期增長72.54%。
綜上各項原因，導致公司淨利潤較上年同期大幅下降。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
